Bioorganic and Medicinal Chemistry Letters p. 2216 - 2220 (2017)
Update date:2022-08-04
Topics:
Salvino, Joseph M.
Srikanth, Yellamelli V.V.
Lou, Rongliang
Oyer, Halley M.
Chen, Nan
Kim, Felix J.
Prostate cancer is the most frequently diagnosed malignancy and the leading cause of cancer related death in men. First line therapy for disseminated disease relies on androgen deprivation, leveraging the addiction of these tumors on androgens for both growth and survival. Treatment typically involves antagonizing the androgen receptor (AR) or blocking the synthesis of androgens. Recurrence is common and within 2–3?years patients develop castration resistant tumors that become unresponsive to AR-axis targeted therapies. In order to provide a more effective treatment, we are utilizing an approach that targets a key scaffolding protein, Sigma1 (also known as sigma-1 receptor), a unique 26-kilodalton integral membrane protein that is critical in stabilizing the AR. Herein we report on a new series of Sigma1 compounds for lead optimization derived from a hybrid pharmacophore approach.
View MoreHunan Haili Chemical Industry Co.,Ltd.
Contact:+86-731-85521860
Address:No.251, 2nd Section, Furong Road, Changsha,Hunan,China
SHANGHAI T&W PHARMACEUTICAL CO., LTD.
website:http://www.trustwe.com
Contact:+86-21-61551611
Address:601, No. 1, 2277 Nong, Zu Chongzhi Road, Zhangjiang Hightech. Park, Pudong
Dongtai Xinyuan Chemical Co., Ltd.
Contact:+86-21-56733000
Address:404F, 99Nong No.117 Zhongtan Rd. Shanghai
Shandong Topscience Biotech Co., Ltd.
Contact:0633-2619278
Address:No. 98 Lanshan West Road, Lanshan District, Rizhao, Shandong Province, P.R. of China
Feiyang Biotechnology Co., Ltd.
Contact:+86-533-7866339
Address:Qilu Chemistry Park, 200m north of Management Community Building of Park
Doi:10.1016/j.tetlet.2014.01.010
(2014)Doi:10.1021/jo402658h
(2014)Doi:10.1002/hc.10129
(2003)Doi:10.1021/om00031a009
(1993)Doi:10.3762/bjoc.14.92
(2018)Doi:10.1039/DT9950000409
(1995)